Kardia Therapeutics Overview

  • Founded
  • 2002

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

Kardia Therapeutics General Information


Developer of a research-stage biotechnology platform designed to focus on the development of cardiac regenerative treatments. The company's platform emphasizes in the areas of myocardial infarction and heart failure by using a three-way related approaches namely, Adult Cardiac Progenitor Cell Therapy, Stem Cell Optimization Technologies and Homing-Growth Factor Therapies, enabling physicians to avail significantly improved health outcomes compared to existing treatments.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Other Healthcare Technology Systems
Primary Office
  • 1709 Dryden Road
  • Suite 910
  • Houston, TX 77030
  • United States
+1 (713) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Kardia Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Out of Business 01-Oct-2018 Completed Out of Business
4. Early Stage VC Completed Startup
3. Grant 01-Jan-2007 00.000 Completed Startup
2. Grant 01-Jan-2005 $526K Completed Startup
1. Grant 01-Jan-2004 $100K Completed Startup
To view Kardia Therapeutics’s complete valuation and funding history, request access »

Kardia Therapeutics Executive Team (2)

Name Title Board Seat Contact Info
Royal Brompton Founder & Scientific Board Member
You’re viewing 1 of 2 executive team members. Get the full list »

Kardia Therapeutics Board Members (1)

Name Representing Role Since
Royal Brompton Kardia Therapeutics Founder & Scientific Board Member 000 0000
To view Kardia Therapeutics’s complete board members history, request access »